Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial
NCT01458327 · Resilient Pharmaceuticals
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Baseline Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV)
Measured over Less than 4 weeks before first experimental session
Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 2-month Follow-up
Measured over 2 months post experimental session
Clinician-Administered PTSD Scale (CAPS-IV)) at 12-month Follow-up
Measured over 12 months post experimental session
Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 2-month Follow-up
Measured over Baseline to 2 months post experimental session
Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 12-month Follow-up
Measured over Baseline to 12 months post experimental session
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| Offices of Michael Mithoefer | Mt. Pleasant | South Carolina | United States |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT01458327 on ClinicalTrials.gov →
Last updated in the registry 2024-01-24. Registry records change; this page reflects the data build of 2026-08-25.
Related